Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002509481 | SCV000756705 | likely benign | not provided | 2023-12-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002325224 | SCV002631431 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-05-20 | criteria provided, single submitter | clinical testing | The p.L14F variant (also known as c.40C>T), located in coding exon 1 of the FH gene, results from a C to T substitution at nucleotide position 40. The leucine at codon 14 is replaced by phenylalanine, an amino acid with highly similar properties. This amino acid position is well conserved on limited sequence alignment. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV002509481 | SCV002818806 | uncertain significance | not provided | 2022-12-23 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Natera, |
RCV000635308 | SCV001455899 | uncertain significance | Fumarase deficiency | 2019-10-28 | no assertion criteria provided | clinical testing |